指南与共识流行病学与生物统计新药、器械与细胞基因治疗研发

WHO 预防 COVID-19 药物动态指南

A living WHO guideline on drugs to prevent covid-19.
指南 / 共识 · BMJ · 2021-03-01

该动态指南由世界卫生组织发布,首版聚焦羟氯喹预防 COVID-19 的证据。基于 6 项试验、6059 名参与者的系统综述与网络荟萃分析,专家组强烈推荐未感染 COVID-19 者不使用羟氯喹(高确定性)。

要点

  • 强烈推荐未感染 COVID-19 者不使用羟氯喹预防(高确定性证据)。
  • 羟氯喹对死亡率、住院及感染影响很小或无影响,但可能增加导致停药的不良事件。
  • 羟氯喹不再作为研究优先方向,资源应转向其他更有希望的预防药物。

核心结论

  • 专家组强烈推荐未感染 COVID-19 的个体不使用羟氯喹预防(高确定性)。

研究设计与样本

  • 世界卫生组织(WHO)发布的动态指南,由 MAGIC 证据生态系统基金会提供方法学支持。
  • 国际指南制定小组包含内容专家、临床医生、患者、伦理学家和方法学家,采用 GRADE 方法制定推荐。
  • 基于动态系统综述与网络荟萃分析(6 项试验,6059 名参与者)形成推荐。

主要发现

  • 羟氯喹对死亡率和住院风险影响很小或无影响(高确定性证据)。
  • 羟氯喹对实验室确诊 SARS-CoV-2 感染影响很小或无影响(中等确定性证据)。
  • 羟氯喹可能增加导致停药的不良事件(中等确定性证据)。

关键数值与推荐

  • 推荐:未感染 COVID-19 者不使用羟氯喹预防(强烈推荐,高确定性)。
  • 专家组判断几乎所有人不会认为该药值得使用。
  • 资源、可行性、可接受性和公平性等背景因素不太可能改变该推荐。

临床怎么用

  • 临床医生不应为未感染 COVID-19 者处方羟氯喹进行预防。
  • 卫生政策与资源应导向评估其他更有希望的 COVID-19 预防药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CLINICAL QUESTION: What is the role of drugs in preventing covid-19? WHY DOES THIS MATTER?: There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline focuses on the evidence for hydroxychloroquine. Subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19. RECOMMENDATION: The guideline development panel made a strong recommendation against the use of hydroxychloroquine for individuals who do not have covid-19 (high certainty). HOW THIS GUIDELINE WAS CREATED: This living guideline is from the World Health Organization (WHO) and provides up to date covid-19 guidance to inform policy and practice worldwide. Magic Evidence Ecosystem Foundation (MAGIC) provided methodological support. A living systematic review with network analysis informed the recommendations. An international guideline development panel of content experts, clinicians, patients, an ethicist and methodologists produced recommendations following standards for trustworthy guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. UNDERSTANDING THE NEW RECOMMENDATION: The linked systematic review and network meta-analysis (6 trials and 6059 participants) found that hydroxychloroquine had a small or no effect on mortality and admission to hospital (high certainty evidence). There was a small or no effect on laboratory confirmed SARS-CoV-2 infection (moderate certainty evidence) but probably increased adverse events leading to discontinuation (moderate certainty evidence). The panel judged that almost all people would not consider this drug worthwhile. In addition, the panel decided that contextual factors such as resources, feasibility, acceptability, and equity for countries and healthcare systems were unlikely to alter the recommendation. The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent covid-19. UPDATES: This is a living guideline. New recommendations will be published in this article and signposted by update notices to this guideline. READERS NOTE: This is the first version of the living guideline for drugs to prevent covid-19. It complements the WHO living guideline on drugs to treat covid-19. When citing this article, please consider adding the update number and date of access for clarity.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Lamontagne F, Stegemann M, Agarwal A, et al. A living WHO guideline on drugs to prevent covid-19. BMJ. 2021. PMID: 33649077. doi:10.1136/bmj.n526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。